12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Gleevec regulatory update

FDA granted full approval to Novartis' Gleevec imatinib for adjuvant treatment of stem cell factor ( SCF) receptor tyrosine kinase (c-Kit; KIT; CD117)-positive gastrointestinal stromal tumors (GIST) for 36 months following surgery. The current standard is adjuvant treatment for 12 months. The...

Read the full 213 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >